Skip to main content
NRXP logo

NRx Pharmaceuticals, Inc.

NRXPNASDAQHealthcareBiotechnology

$2.60Today:- (-)1Y −14.78%

As of Oct 16, 2026 close

Market cap
$102.03M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.62$5.06
Volume (live)
-
Avg. volume (3M)
684.66K

NRx Pharmaceuticals (NRXP) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), NRx Pharmaceuticals used $14.11M of cash in operating activities. Free cash flow was −$14.11M.

NRx Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for NRx Pharmaceuticals, Inc. (NRXP) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2023FY 2022FY 2021FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Mar 2024Dec 2023Dec 2022Mar 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-28.62-25.13-30.15-30.15-39.75-93.06-93.06-51.780.410.07-0.11
Depreciation & Amortization0.140.010.010.010.000.000.000.000.000.000.00
Stock Based Compensation0.230.520.390.390.007.797.790.730.000.000.00
Change in Working Capital1.415.295.165.160.70-4.90-4.903.450.000.550.00
Change in Accounts Receivable0.050.000.00-0.000.830.83-0.830.000.000.00
Change in Accounts Payable0.11-5.222.662.660.00-0.02-0.021.180.000.470.09
Change in Other Working Capital1.250.502.512.960.70-5.7154.283.100.000.08-0.09
Other Operating Activities12.738.712.942.96-0.7052.4754.2845.31-1.21-1.55-0.12
Net Cash from Operating Activities-14.11-10.64-21.66-21.66-39.76-37.70-37.70-2.27-0.79-0.47-0.14
Investing Activities
Capital Expenditures0.000.000.000.000.00-0.01-0.010.000.000.000.00
Acquisitions-2.380.000.00-0.000.00-0.000.000.000.00
Purchases of Investments-0.430.000.00--0.010.00-0.00-0.99-0.69-69.00
Sales/Maturities of Investments0.000.000.00-0.000.00-0.0041.240.040.00
Other Investing Activities0.000.000.00-0.000.00-0.000.00-0.65-69.00
Net Cash from Investing Activities-2.810.000.000.00-0.01-0.01-0.010.0040.25-0.65-69.00
Financing Activities
Debt Repayment7.42-8.58-3.09-4.049.50-1.28-1.280.621.260.690.00
Common Stock Issued15.869.888.128.1222.7136.9836.982.580.00-0.0169.59
Common Stock Repurchased0.000.000.00-0.000.00-0.00-40.730.0070.03
Other Financing Activities0.003.071.17-0.0027.7511.050.050.000.000.00
Net Cash from Financing Activities23.287.496.206.2032.2163.4663.463.25-39.460.6869.59
Summary
Net Change in Cash6.35-3.15-15.46-15.46-7.5525.7525.750.98-0.01-0.440.45
Cash at Beginning of Period1.444.6020.0520.0527.611.861.860.880.010.450.00
Cash at End of Period7.801.444.604.6020.0527.6127.611.860.000.010.45
Free Cash Flow-14.11-10.64-21.66-21.66-39.76-37.71-37.71-2.27-0.79-0.47-0.14
Supplemental Disclosures
Interest Paid-0.37-0.89-------

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About NRx Pharmaceuticals Cash Flow

What is NRx Pharmaceuticals's free cash flow?

NRx Pharmaceuticals had negative free cash flow of $14.11M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does NRx Pharmaceuticals pay dividends or buy back shares?

NRx Pharmaceuticals's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition